What question did this study set out to answer?

To establish a causal failure-attribution framework examining why central nervous system docosahexaenoic acid (DHA) target engagement failed to produce clinical or structural brain benefits in the PreventE4 trial.

September 2, 2026Open Access

When CNS DHA Target Engagement Does Not Translate into Clinical Benefit

View Full Paper

Ask AI

Bookmark

Authors

MBMohammed El Amin Bouchelit

Discussion

Member takes

Overview

Randomized double-blind trial demonstrates robust CSF DHA target engagement without cognitive or volumetric benefit in older adults at risk for dementia, suggesting downstream execution failure.

Key Points

To establish a causal failure-attribution framework examining why central nervous system docosahexaenoic acid (DHA) target engagement failed to produce clinical or structural brain benefits in the PreventE4 trial.
PreventE4 was a phase IIa, 24-month, randomized, double-blind, placebo-controlled trial evaluating 2 g/day oral DHA versus placebo in 365 cognitively unimpaired adults aged 55–80 years with low dietary DHA intake and dementia risk factors.
A subset of 181 participants underwent lumbar punctures to evaluate changes in cerebrospinal fluid (CSF) DHA-to-arachidonic-acid (AA) ratios at 6 months, stratified by APOE ε4 status.
The HISTAMOS Failure Attribution Standard pre-specified downstream causal layers, including neuronal membrane utilization, lipid-stress handling, and mitochondrial capacity, prior to unblinding participant-level secondary data.
DHA increased the 6-month CSF DHA/AA ratio by 0.17 (95% CI 0.15–0.18) versus −0.02 (95% CI −0.04 to −0.0004) with placebo, achieving a between-group difference of 0.19 (95% CI 0.16–0.21; p<0.0001).
The primary biochemical target-engagement response did not differ by APOE ε4 carrier status (interaction p=0.71).
No group-level treatment differences were detected in cognitive performance or brain volumes over 24 months, indicating that central biochemical exposure alone was insufficient to confer functional benefit.

Cite This Study

Mohammed El Amin Bouchelit (2026) studied this question.

synapsesocial.com/papers/6a97e2b1c562ede874ec6e5a https://doi.org/10.5281/zenodo.22207326

View Full Paper

Ask AI

Bookmark

September 2, 2026Open Access

When CNS DHA Target Engagement Does Not Translate into Clinical Benefit

View Full Paper

Ask AI

Bookmark

Authors

MBMohammed El Amin Bouchelit

Discussion

Member takes

Overview

Randomized double-blind trial demonstrates robust CSF DHA target engagement without cognitive or volumetric benefit in older adults at risk for dementia, suggesting downstream execution failure.

Key Points

To establish a causal failure-attribution framework examining why central nervous system docosahexaenoic acid (DHA) target engagement failed to produce clinical or structural brain benefits in the PreventE4 trial.
PreventE4 was a phase IIa, 24-month, randomized, double-blind, placebo-controlled trial evaluating 2 g/day oral DHA versus placebo in 365 cognitively unimpaired adults aged 55–80 years with low dietary DHA intake and dementia risk factors.
A subset of 181 participants underwent lumbar punctures to evaluate changes in cerebrospinal fluid (CSF) DHA-to-arachidonic-acid (AA) ratios at 6 months, stratified by APOE ε4 status.
The HISTAMOS Failure Attribution Standard pre-specified downstream causal layers, including neuronal membrane utilization, lipid-stress handling, and mitochondrial capacity, prior to unblinding participant-level secondary data.
DHA increased the 6-month CSF DHA/AA ratio by 0.17 (95% CI 0.15–0.18) versus −0.02 (95% CI −0.04 to −0.0004) with placebo, achieving a between-group difference of 0.19 (95% CI 0.16–0.21; p<0.0001).
The primary biochemical target-engagement response did not differ by APOE ε4 carrier status (interaction p=0.71).
No group-level treatment differences were detected in cognitive performance or brain volumes over 24 months, indicating that central biochemical exposure alone was insufficient to confer functional benefit.

Cite This Study

Mohammed El Amin Bouchelit (2026) studied this question.

synapsesocial.com/papers/6a97e2b1c562ede874ec6e5a https://doi.org/10.5281/zenodo.22207326

View Full Paper

Ask AI

Bookmark